Public Charity

CONGENITAL HYPERINSULINISM INTERNATIONAL

Based in GLEN RIDGE, NJ, CONGENITAL HYPERINSULINISM INTERNATIONAL operates as a Public Charity. The organization reported $1.3M in revenue, $1.1M in expenses, $2.2M in total assets for fiscal year 2024. Imperigo tracks 25 reported grant relationships connected to this organization totaling approximately $871K.

EIN: 203068945 GLEN RIDGE, NJ Fund Raising & Fund Distribution NTEE: G12 Latest filing: 2024
Total Revenue$1.3M
Total Expenses$1.1M
Total Assets$2.2M
Grant Records25
Funding Total$871K
Filing Years2019–2024

Mission

Congenital Hyperinsulinism International (CHI) is a nonprofit 501(c)(3) corporation dedicated to improving the lives of babies, children, and adults affected by congenital hyperinsulinism (HI). HI is a life-threatening genetic disorder that causes severe low blood sugar (hypoglycemia) in infants and children, though in 50% of patients, the genetic cause is unknown. For those with HI, the beta cells of the pancreas secrete too much insulin in an unregulated manner. Excess insulin causes hypoglycemia. Prolonged or severe hypoglycemia can cause seizures, permanent brain damage, or even death if left untreated. A good prognosis is far more likely with a timely diagnosis and proper management.

Where $100 goes at Congenital Hyperinsulinism International

How Congenital Hyperinsulinism International divides every $100 it spends, from its own Form 990 filings, averaged across 7 years.

$87 Programs the work itself
$5 Management running the organization
$8 Fundraising raising the next dollar

Inside the $87 for programs

$50
CHI supports research and development to better understand, treat, manage, and hopefully cure HI
58% of program spending · Reported in the filing: 17 members; 1,001 individuals; 731 members
$20
CHI increases awareness of HI to improve timely diagnosis and guideline-driven management of HI to the public and medical personnel who have a direct opportunity to detect it…
23% of program spending
$17
CHI advocates on behalf of HI families all over the world for access to quality treatment, medication, and supplies
19% of program spending
Share on LinkedIn Share on Facebook
Add this to your website

Source: Form 990 filings with the IRS, latest fiscal year 2024. Shares are from the organization's reported expenses. Data by Imperigo; not affiliated with the IRS.

Officers & Directors

COO Jennifer Schmitt
CEO Julie Raskin
Vice President Julie Sheldon
Director Justyna Montemurro
President Laura Sullivan
Treasurer Mason Smith

Officer compensation and complete director data available with membership.

Top Grant Purposes

Health & Medicine
$630,000 3 grants
General Support
$211,058 18 grants
Fundraising & Sponsorship
$30,000 3 grants

Financial Trends

Year Revenue Expenses Assets
2024 $1.3M $1.1M $2.2M
2023 $1.2M $1.0M $1.8M
2022 $1.3M $834K $1.6M
2020 $708K $468K $1.1M
2019 $467K $495K $593K

Between 2019 and 2024, reported annual revenue grew from $467K to $1.3M (+173%), with total assets most recently reported at $2.2M.

Interactive year-over-year charts and full filing details available with membership.

See the full picture for CONGENITAL HYPERINSULINISM INTERNATIONAL

Complete financials, all 25 grant records, officer compensation, year-over-year trend charts, a geographic grant map, and data exports — across 880,000+ organizations.

Full Financial History Complete Grant Activity Officer Compensation Year-over-Year Charts Geographic Grant Map Data Exports
7-day free trial Cancel any time